Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published May 2020
  • Article
  • Info & Metrics
  • PDF
Loading

A Novel DNA-PK Inhibitor May Offer a New Treatment Option for Patients with Cancer Undergoing Radiotherapy

Zenke et al. Page 1091

Radiotherap. is a mainstay of cancer treatment and improvements in efficacy are long awaited. DNA-dependent protein kinase (DNA-PK) is a key driver of one of the main DNA repair pathways. Zenke and colleagues report a new generation, potent, selective, and orally bioavailable DNA PK inhibitor, M3814. This agent effectively blocks the repair of DNA double-strand breaks and strongly potentiates the efficacy of ionizing radiation in multiple cancer cell lines. M3814 in combination with fractionated radiation treatment was well tolerated and led to effective human tumor regression in mouse xenograft models. M3814 may offer a novel treatment modality in combination with radiotherapy.

Inhibiting Fucosylation to Treat and Prevent Breast Cancer

Disis et al. Page 1102

Transgenic mouse models of breast cancer have demonstrated that despite only moderate levels of infiltrating lymphocytes, significant levels of anti-tumor IgG antibodies are present. Knowing that a fucosylation of antibodies markedly enhances antibody-dependent cellular cytotoxicity (ADCC), Disis and colleagues employed the fucosylation inhibitor 2FF in these breast cancer models. 2FF treatment generated immunity in transgenic luminal B and basal mammary cancers. Tumor lysis was reproducible using serum derived from 2FF-treated mice. 2FF was also able to delay the onset of tumors in the transgenic models. 2FF therefore represents a means by which endogenous IgG antibodies specific for breast cancer antigens can be exploited for cancer therapy and prevention.

SLFN11 Expression in Prostate Cancer

Conteduca et al. Page 1157

Clinical trials using platinum compounds in castration-resistant prostate cancer (CRPC) have shown profound responders juxtaposed with those who gained no significant overall survival benefit. As platinum may also be used in patients with metastatic CRPC, biomarkers are needed to determine those who would benefit from its use. Conteduca and colleagues characterize the contribution of SLFN11, a DNA/RNA helicase with a history predicting DNA damaging agents, to platinum therap. in CRPC patients. Assessing a total of 41 patients, they determined that SLFN11 overexpression predicted radiographic progression-free survival in metastatic tumors and associated with an over 50% reduction in prostate-specific antigen. Taken together, SLFN11 was an independent factor that predicts response to platinum therapy in CRPC patients and warrants further study including in the context of PARP inhibitors.

CDK9 Inhibitors Synergize with Mithramycin for Ewing Sarcoma

Flores et al. Page 1183

Mithramycin is a potent inhibitor of the EWS-FLI1 transcription factor on which Ewing sarcoma is dependent. Due to liver toxicity observed in phase I/II clinical trials, Flores and colleagues sought to find a means to potentiate lower doses of mithramycin and avoid compounding toxicity. They found that inhibiting CDK9 simultaneously generated cytotoxicity in Ewing sarcoma cells and limited the BTG2-dependent loss of liver cell viability. Addition of the CDK9 inhibitor PHA-767491 with mithramycin allowed a five-fold reduction in the concentration of mithramycin necessary to achieve this tumor cell cytotoxicity. Their results demonstrate a less toxic approach to EWS-FL1 targeted therapy in Ewing sarcoma.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (5)
May 2020
Volume 19, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Mol Cancer Ther May 1 2020 (19) (5) 1089;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Mol Cancer Ther May 1 2020 (19) (5) 1089;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • A Novel DNA-PK Inhibitor May Offer a New Treatment Option for Patients with Cancer Undergoing Radiotherapy
    • Inhibiting Fucosylation to Treat and Prevent Breast Cancer
    • SLFN11 Expression in Prostate Cancer
    • CDK9 Inhibitors Synergize with Mithramycin for Ewing Sarcoma
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement